This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. AI is making waves Recursion Pharmaceuticals reported positive Phase 1b/2 data for its AI-discovered drug REC-4881 from the ongoing TUPELO trial. REC-4881 is an allosteric MEK1/
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. Replacing Animal Testing: A New Regulatory Era Animal testing in drug discovery has long been the subject of multifaceted debate. On one hand, it has been — until
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. We’re already halfway through November — and what a year it’s been! From LLMs becoming mainstream to AI-generated and AI-discovered drugs reaching patients, 2025 will be
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. I believe in two things: AI is here to stay — and AI will transform how we treat diseases. By now, I think we all agree on the
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. The Industrialization of Discovery: Pharma Builds the Engine Almost a decade ago, generative AI in small molecule drug design dominated the conversation. Today, as that area grapples
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. From Potential to Practice: The Hard Work of Implementation Continues A decade ago, I entered the healthcare and life sciences world from a pure AI background. Over
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. Data, Deals, and Geopolitics For the last year, we've watched the rise of massive, centralized AI models. The logical next step, many assumed, was that
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. The Great Divergence: AI Healthtech Splits from the Pack For the past year, a sense of caution has settled over the biotech sector. The exuberant post-pandemic funding
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. AI in Bio Is Becoming Plumbing (and That’s When the Strategy Gets Interesting) The last few weeks in AI and bio have been contradictory. On one
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. Every truly foundational technology eventually transitions from a technical question to a political one. For AI, that slow transition from the abstract to the concrete is now
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. The End of the Beginning: From Models to Stacks There's a familiar pattern to how transformative technologies mature. First comes the explosion of new tools
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. Issue #2: From Potential to Practice: The Rise of the Regulatory Stack If early June was all about building sovereign AI capabilities (check the previous issue), the
This isn’t a recap of the weeks—it’s an attempt to understand the forces reshaping how we live, govern, and evolve. Issue #1: The Sovereignty Race in Bio-AI For years, the dominant question in Bio-AI was: Whose model is best? We obsessed over architectures, training efficiency, and the